Mangoceuticals, Inc. Common Stock (MGRX NASDAQ) stock market data APIs
$1.743
0.02(1.1%)
as of June 27, 2025
Try our APIs with
free plan!
Mangoceuticals, Inc. Common Stock Financial Data Overview
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. The company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Prev. Close
1.743
Open
1.7602
High
1.7981
Low
1.687
52 wk Range
1.32-7.05
Market Cap
18 415 K
Shares Outstanding
10 645 K
Revenue
511 K
EPS
-1.0536
Beta
2.763
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mangoceuticals, Inc. Common Stock data using free add-ons & libraries
Get Mangoceuticals, Inc. Common Stock Fundamental Data
Mangoceuticals, Inc. Common Stock Fundamental data includes:
- Net Revenue: 511 K
- EBITDA: -8 309 112
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mangoceuticals, Inc. Common Stock News
New
Mangoceuticals files $150M mixed securities shelf
* Mangoceuticals (NASDAQ:MGRX [https://seekingalpha.com/symbol/MGRX]) filed $150M mixed securities shelf. * Filing [https://seekingalpha.com/filing/10098315] MORE ON MANGOCEUTICALS * Financial information for Mangoceuticals [https://seekingalpha.com/symbol/MGRX/income-statement]
Mangoceuticals files to sell 4.46M shares of common stock by selling shareholders
* Mangoceuticals (MGRX [https://seekingalpha.com/symbol/MGRX]) filed a prospectus to resale 4.46M shares of common stock. * The company will not receive any proceeds from the sale of ordinary sha...
Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division
DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ: MGRX) (“Mangoceuticals” or “MGRX”), a company focused on developing, marketing, and selling a variety of health an...
Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation
Dallas, TX & Quebec, Canada, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of men’s wellness products and...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
